SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012; 62: 10-29.
  • 2
    Jayaraman S, Jarnagin WR. Management of gallbladder cancer. Gastroenterol Clin North Am. 2010; 39: 331-342, x.
  • 3
    Dixon E, Vollmer CM Jr, Sahajpal A, et al. An aggressive surgical approach leads to improved survival in patients with gallbladder cancer: a 12-year study at a North American center. Ann Surg. 2005; 241: 385-394.
  • 4
    Mayo SC, Shore AD, Nathan H, et al. National trends in the management and survival of surgically managed gallbladder adenocarcinoma over 15 years: a population-based analysis. J Gastrointest Surg. 2010; 14: 1578-1591.
  • 5
    de Groen PC, Gores GJ, LaRusso NF, Gunderson LL, Nagorney DM. Biliary tract cancers. N Engl J Med. 1999; 341: 1368-1378.
  • 6
    Leonard GD, O'Reilly EM. Biliary tract cancers: current concepts and controversies. Expert Opin Pharmacother. 2005; 6: 211-223.
  • 7
    Takada T, Amano H, Yasuda H, et al. Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? A phase III multicenter prospective randomized controlled trial in patients with resected pancreaticobiliary carcinoma. Cancer. 2002; 95: 1685-1695.
  • 8
    Zhu AX, Hong TS, Hezel AF, Kooby DA. Current management of gallbladder carcinoma. Oncologist. 2010; 15: 168-181.
  • 9
    Alvaro D, Cannizzaro R, Labianca R, Valvo F, Farinati F; Italian Society of Gastroenterology (SIGE), Italian Association of Hospital Gastroenterology (AIGO), Italian Association of Medical Oncology (AIOM), Italian Association of Oncological Radiotherapy (AIRO). Cholangiocarcinoma: a position paper by the Italian Society of Gastroenterology (SIGE), the Italian Association of Hospital Gastroenterology (AIGO), the Italian Association of Medical Oncology (AIOM) and the Italian Association of Oncological Radiotherapy (AIRO). Dig Liver Dis. 2010; 42: 831-838.
  • 10
    Murakami Y, Uemura K, Sudo T, et al. Prognostic factors after surgical resection for intrahepatic, hilar, and distal cholangiocarcinoma. Ann Surg Oncol. 2011; 18: 651-658.
  • 11
    Valle J, Wasan H, Palmer DH, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010; 362: 1273-1281.
  • 12
    Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001; 344: 783-792.
  • 13
    Giovannetti E, Mey V, Nannizzi S, Pasqualetti G, Del Tacca M, Danesi R. Pharmacogenetics of anticancer drug sensitivity in pancreatic cancer. Mol Cancer Ther. 2006; 5: 1387-1395.
  • 14
    Nakano Y, Tanno S, Koizumi K, et al. Gemcitabine chemoresistance and molecular markers associated with gemcitabine transport and metabolism in human pancreatic cancer cells. Br J Cancer. 2007; 96: 457-463.
  • 15
    Giovannetti E, Del Tacca M, Mey V, et al. Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine. Cancer Res. 2006; 66: 3928-3935.
  • 16
    Mori R, Ishikawa T, Ichikawa Y, et al. Human equilibrative nucleoside transporter 1 is associated with the chemosensitivity of gemcitabine in human pancreatic adenocarcinoma and biliary tract carcinoma cells. Oncology Rep. 2007; 17: 1201-1205.
  • 17
    Tsujie M, Nakamori S, Nakahira S, et al. Human equilibrative nucleoside transporter 1, as a predictor of 5-fluorouracil resistance in human pancreatic cancer. Anticancer Res. 2007; 27( 4B): 2241-2249.
  • 18
    Mini E, Nobili S, Caciagli B, Landini I, Mazzei T. Cellular pharmacology of gemcitabine. Ann Oncol. 2006; 17(suppl 5): v7-v12.
  • 19
    Nakahira S, Nakamori S, Tsujie M, et al. Involvement of ribonucleotide reductase M1 subunit overexpression in gemcitabine resistance of human pancreatic cancer. Int J Cancer. 2007; 120: 1355-1363.
  • 20
    Duxbury MS, Ito H, Zinner MJ, Ashley SW, Whang EE. RNA interference targeting the M2 subunit of ribonucleotide reductase enhances pancreatic adenocarcinoma chemosensitivity to gemcitabine. Oncogene. 2004; 23: 1539-1548.
  • 21
    Liu X, Lai L, Wang X, et al. Ribonucleotide reductase small subunit M2B prognoses better survival in colorectal cancer. Cancer Res. 2011; 71: 3202-3213.
  • 22
    Gossage L, Madhusudan S. Current status of excision repair cross complementing-group 1 (ERCC1) in cancer. Cancer Treat Rev. 2007; 33: 565-577.
  • 23
    Ansari D, Rosendahl A, Elebro J, Andersson R. Systematic review of immunohistochemical biomarkers to identify prognostic subgroups of patients with pancreatic cancer. Br J Surg. 2011; 98: 1041-1055.
  • 24
    Jordheim LP, Seve P, Tredan O, Dumontet C. The ribonucleotide reductase large subunit (RRM1) as a predictive factor in patients with cancer. Lancet Oncol. 2011; 12: 693-702.
  • 25
    Andrews J, Yeh P, Pao W, Horn L. Molecular predictors of response to chemotherapy in non-small cell lung cancer. Cancer J. 2011; 17: 104-113.
  • 26
    Fisher SB, Patel SH, Baqci P, et al. An analysis of human equiliberative nucleoside transporter-1, ribonucleoside reductase subunit M1, ribonucleoside reductase subunit M2, and excision repair cross-complementing gene-1 expression in patients with resected pancreas adenocarcinoma: implications for adjuvant treatment [published online ahead of print May 8, 2012]. Cancer. 2012.
  • 27
    Maithel SK, Coban I, Kneuertz PJ, et al. Differential expression of ERCC1 in pancreas adenocarcinoma: high tumor expression is associated with earlier recurrence and shortened survival after resection. Ann Surg Oncol. 2011; 18: 2699-2705.
  • 28
    Roa I, de Aretxabala X, Lantadilla S, Munoz S. ERCC1 (excision repair cross-complementing 1) expression in pT2 gallbladder cancer is a prognostic factor. Histol Histopathol. 2011; 26: 37-43.
  • 29
    Ohtaka K, Kohya N, Sato K, et al. Ribonucleotide reductase subunit M1 is a possible chemoresistance marker to gemcitabine in biliary tract carcinoma. Oncol Rep. 2008; 20: 279-286.
  • 30
    Nakamura J, Kohya N, Kai K, et al. Ribonucleotide reductase subunit M1 assessed by quantitative double-fluorescence immunohistochemistry predicts the efficacy of gemcitabine in biliary tract carcinoma. Int J Oncol. 2010; 37: 845-852.
  • 31
    Wakai T, Shirai Y, Sakata J, et al. Ribonucleotide reductase M1 expression in intrahepatic cholangiocarcinoma. Hepatogastroenterology. 2011; 58: 1659-1663.
  • 32
    Ferrandina G, Mey V, Nannizzi S, et al. Expression of nucleoside transporters, deoxycitidine kinase, ribonucleotide reductase regulatory subunits, and gemcitabine catabolic enzymes in primary ovarian cancer. Cancer Chemother Pharmacol. 2010; 65: 679-686.
  • 33
    Mackey JR, Jennings LL, Clarke ML, et al. Immunohistochemical variation of human equilibrative nucleoside transporter 1 protein in primary breast cancers. Clin Cancer Res. 2002; 8: 110-116.
  • 34
    Borbath I, Verbrugghe L, Lai R, et al. Human equilibrative nucleoside transporter 1 (hENT1) expression is a potential predictive tool for response to gemcitabine in patients with advanced cholangiocarcinoma. Eur J Cancer. 2012; 48: 990-996.
  • 35
    Santini D, Schiavon G, Vincenzi B, et al. Human equilibrative nucleoside transporter 1 (hENT1) levels predict response to gemcitabine in patients with biliary tract cancer (BTC). Curr Cancer Drug Targets. 2011; 11: 123-129.